Amre A. Elmaoued, PharmD, PhC, BCPP

Incretin therapies have emerged as a promising treatment option with potential benefits for mitigating cardiometabolic side effects associated with antipsychotics; however, clinical trials have often excluded psychiatric populations.

This case demonstrates that LAI risperidone may support emotional and interpersonal improvements in a patient with both borderline personality disorder and autism spectrum disorder.

After a failed trial of prazosin, a switch to terazosin was efficacious in reducing the severity and frequency of trauma-related nightmares.